Table 1. Potential Variations of the HBV Genome Associated With Fulminant Outcome and Their Effects a.
| ORF | HBV nt or aa Variation | Effect |
|---|---|---|
| C | ||
| BCP/PC | T1753C/A/G, T1754C/G | decreased HBeAg production , enhanced replication |
| A1762T + G1764A | HNF3 binding site formation, decreased HBeAg production enhanced replication | |
| G1764T + C1766G | HNF1 binding site formation, enhanced replication | |
| C1766T + T1768A | enhanced replication | |
| 11bp insertion: 1775 - 1776 | HNF1 binding site formation, enhanced replication | |
| T1825C + A1827C | may affect the HBV life cycle | |
| G1896A + G1899A | abolished HBeAg expression, enhanced replication | |
| G1862A | decreased HBeAg production enhanced replication | |
| Core | T1961C/A/G C1962D | T cell epitope alteration |
| A2339G | T cell epitope alteration, enhanced replication | |
| X | xI127T, xK130M xV131I, xF132Y | “hotspot” mutations may enhance or disrupt the replication |
| S | ||
| Pre-S1/Pre-S2 | Pre-S insertion, deletion or missense mutations | defective Pre-S proteins, T and B cell epitopes alteration, imbalance of S protein synthesis and intracellular retention, cytotoxicity |
| HBsAg | Immune escape mutations sM125T, sT127P, sG145R | vaccine and HBIG therapy failure, reduced virion secretion, enhanced replication |
| P | RT mutations pR/W153Q, pL180M + pM204V | restored HBV replication, LAM resistance |
a Abbreviations: ORF, Open Reading Frame; nt, nucleotide; aa, amino acid; RT, Reverse Transcriptase; LAM, Lamivudine.